Last reviewed · How we verify
with concurrent cisplatin chemotherapy
This is a concurrent chemotherapy regimen combining an unspecified agent with cisplatin to enhance cytotoxic effects against cancer cells.
This is a concurrent chemotherapy regimen combining an unspecified agent with cisplatin to enhance cytotoxic effects against cancer cells. Used for Cancer treatment (specific indication unknown; Phase 3 trial at Fujian Cancer Hospital).
At a glance
| Generic name | with concurrent cisplatin chemotherapy |
|---|---|
| Sponsor | Fujian Cancer Hospital |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin is a platinum-based chemotherapy agent that forms DNA adducts and crosslinks, leading to cell death. When used concurrently with another chemotherapeutic agent, the combination aims to achieve synergistic or additive anti-tumor effects. The specific mechanism of the unnamed concurrent agent cannot be determined without additional information.
Approved indications
- Cancer treatment (specific indication unknown; Phase 3 trial at Fujian Cancer Hospital)
Common side effects
- Nephrotoxicity
- Ototoxicity
- Myelosuppression
- Nausea and vomiting
- Neuropathy
Key clinical trials
- Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy (PHASE2)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (NA)
- Comparing Postoperative Adjuvant Cisplatin Concurrent Chemoradiotherapy With Adjuvant Radiotherapy Alone for Intermediate-risk Head and Neck Squamous Cell Carcinoma (PHASE3)
- A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder (PHASE3)
- Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- with concurrent cisplatin chemotherapy CI brief — competitive landscape report
- with concurrent cisplatin chemotherapy updates RSS · CI watch RSS
- Fujian Cancer Hospital portfolio CI